MDGL Relative Valuation
MDGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MDGL is overvalued; if below, it's undervalued.
Historical Valuation
Madrigal Pharmaceuticals Inc (MDGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.41 is considered Undervalued compared with the five-year average of -9.95. The fair price of Madrigal Pharmaceuticals Inc (MDGL) is between 346.73 to 609.07 according to relative valuation methord. Compared to the current price of 344.97 USD , Madrigal Pharmaceuticals Inc is Undervalued By 0.51%.
Relative Value
Fair Zone
346.73-609.07
Current Price：344.97
0.51%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
9.71
P/B
Median3y
38.82
Median5y
25.90
-5.58
FCF Yield
Median3y
-8.54
Median5y
-9.44
Competitors Valuation Multiple
The average P/S ratio for MDGL's competitors is 5.18, providing a benchmark for relative valuation. Madrigal Pharmaceuticals Inc Corp (MDGL) exhibits a P/S ratio of 9.41, which is 81.81% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Madrigal Pharmaceuticals Inc (MDGL) currently overvalued or undervalued?
What is Madrigal Pharmaceuticals Inc (MDGL) fair value?
How does MDGL's valuation metrics compare to the industry average?
What is the current P/B ratio for Madrigal Pharmaceuticals Inc (MDGL) as of Jul 17 2025?
What is the current FCF Yield for Madrigal Pharmaceuticals Inc (MDGL) as of Jul 17 2025?
What is the current Forward P/E ratio for Madrigal Pharmaceuticals Inc (MDGL) as of Jul 17 2025?